Topical use of topical fibrin sealant can reduce the need for transfusion, total blood loss and the volume of drainage in total knee and hip arthroplasty: A systematic review and meta-analysis of 1489 patients

Li, Jie; Li, Hongbiao; Zhai, Xicheng; Qin-lei,; Jiang, Xin-qiang; Zhang, Zhenhua

doi:10.1016/j.ijsu.2016.10.022

Cited by 35 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, its application has been consolidated in surgical procedures as an efficient method to avoid suturing, decrease recovery time and increase the success rate. Its indications are well defined and proven through a systematic review of studies and meta-analysis [42–45]. Among the unsolved problems, especially in biopharmaceutical production, are the high costs and transmission of infectious diseases by human blood [3, 4].…”

Section: Discussionmentioning

confidence: 99%

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Ferreira

Barros

Abbade

et al. 2017

J Venom Anim Toxins Incl Trop Dis

View full text Add to dashboard Cite

Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.Electronic supplementary materialThe online version of this article (doi:10.1186/s40409-017-0109-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Ferreira

Barros

Abbade

et al. 2017

J Venom Anim Toxins Incl Trop Dis

View full text Add to dashboard Cite

show abstract

“…Studies shown that administration hemostasis agent alone is not sufficient to reach the satisfactory results. [15,16] A previous meta-analysis identified the efficacy of TXA in reducing blood loss after TKA and THA. [16] Anderson et al [17] reported that intra-articular injections of DEP decreased total blood loss after TKA.…”

Section: Discussionmentioning

confidence: 99%

“…What's more, blood loss will also increase the rate of blood transfusion. [2] Blood transfusion is certainly not a zero-risk procedure and may cause postoperative infections and disease transmission. [3] Therefore, it is necessary to explore an efficient protocol to decrease perioperative blood loss in TKA and THA.…”

Section: Introductionmentioning

confidence: 99%

Tranexamic acid plus diluted-epinephrine versus tranexamic acid alone for blood loss in total joint arthroplasty

Yao

Yang

2017

Medicine

View full text Add to dashboard Cite

show abstract

“…It is most commonly used as a surgical sealant and hemostatic agent, where it is quite effective. Fibrin, a product of the action of thrombin on fibrinogen, is the most abundant component of a platelet blood clot [28,73]. Like collagen, it is thought to enhance angiogenesis, granulation tissue formation, and fibroblast proliferation to promote wound healing [14,74].…”

Section: Biomaterials In Clinical Usementioning

confidence: 99%

Minimizing Skin Scarring through Biomaterial Design

Moore

Longaker

2017

JFB

View full text Add to dashboard Cite

Wound healing continues to be a major burden to patients, though research in the field has expanded significantly. Due to an aging population and increasing comorbid conditions, the cost of chronic wounds is expected to increase for patients and the U.S. healthcare system alike. With this knowledge, the number of engineered products to facilitate wound healing has also increased dramatically, with some already in clinical use. In this review, the major biomaterials used to facilitate skin wound healing will be examined, with particular attention allocated to the science behind their development. Experimental therapies will also be evaluated.

show abstract

Topical use of topical fibrin sealant can reduce the need for transfusion, total blood loss and the volume of drainage in total knee and hip arthroplasty: A systematic review and meta-analysis of 1489 patients

Abstract: The topical use of fibrin sealant can effectively reduce the need for transfusion, total blood loss and the volume of drainage without increasing the rate of infection.

Cited by 35 publications

References 29 publications

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Tranexamic acid plus diluted-epinephrine versus tranexamic acid alone for blood loss in total joint arthroplasty

Minimizing Skin Scarring through Biomaterial Design

Contact Info

Product

Resources

About